BioAtla (BCAB) Liabilities and Shareholders Equity (2020 - 2026)
BioAtla (BCAB) posted quarterly Liabilities and Shareholders Equity of $4.3 million for Q4 2025, down 91.83% year-over-year from $52.4 million in Q4 2024, and down 73.06% quarter-over-quarter from $15.9 million in Q3 2025.
BioAtla (BCAB) Liabilities and Shareholders Equity (2020 - 2026) Analysis & Trends
BioAtla's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $4.3 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 91.83% year-over-year to $4.3 million; the TTM figure through Mar 2026 stood at $47.3 million (down 78.64% YoY), while the FY2025 annual figure was $4.3 million, down 91.83% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $4.3 million, down from $15.9 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $277.6 million in Q3 2021, with the low at $4.3 million in Q4 2025.
- The 5-year median for Liabilities and Shareholders Equity is $165.5 million (2023), against an average of $142.5 million.
- The sharpest annual moves came in 2021 and 2025: Liabilities and Shareholders Equity gained 3.87% in 2021, then plunged 91.83% in 2025.
- BioAtla's Liabilities and Shareholders Equity stood at $254.4 million in 2021, then slipped by 11.27% to $225.7 million in 2022, then sank by 46.99% to $119.7 million in 2023, then slumped by 56.19% to $52.4 million in 2024, then slumped by 91.83% to $4.3 million in 2025.
- Business Quant data shows BCAB's Liabilities and Shareholders Equity at $4.3 million in Q4 2025, $15.9 million in Q3 2025, and $27.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.10 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | BioAtla | 5.41 Mn | 5.41 Mn | - | 1.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.28 Mn |
| Mar 31, 2026 | 8.57 Mn |
| Dec 31, 2025 | 4.29 Mn |
| Sep 30, 2025 | 15.91 Mn |
| Jun 30, 2025 | 27.13 Mn |
| Mar 31, 2025 | 38.29 Mn |
| Dec 31, 2024 | 52.42 Mn |
| Sep 30, 2024 | 62.24 Mn |
| Jun 30, 2024 | 68.64 Mn |
| Mar 31, 2024 | 89.20 Mn |
| Dec 31, 2023 | 119.66 Mn |
| Sep 30, 2023 | 151.36 Mn |
| Jun 30, 2023 | 179.64 Mn |
| Mar 31, 2023 | 204.55 Mn |
| Dec 31, 2022 | 225.74 Mn |
| Sep 30, 2022 | 189.11 Mn |
| Jun 30, 2022 | 213.50 Mn |
| Mar 31, 2022 | 230.65 Mn |
| Dec 31, 2021 | 254.42 Mn |
| Sep 30, 2021 | 277.58 Mn |